ReviewJournal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG2019
Vulvar malignancies: an interdisciplinary perspective.
Review in Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 48 citations in OpenAlex.
- Article
- Article
- Vulvovaginal tumors and pseudo-tumors: a clinicopathological analysis of 57 cases.BMC research notes · 2026Article
- INHBA: A Protein-coding Gene Closely Related to Tumour Diseases.Current topics in medicinal chemistry · 2026Review
- Temporal Trends in Vulvar Cancer Cases and Associated Factors of Adverse Clinical Features: A 6-year Retrospective Study From a Tertiary Hospital in Indonesia.International journal of women's health · 2026Article
- Combinatorial Effects of Plasma-Treated Solution and Plasma-Treated Hydrogel with Cisplatin in Vulvar Cancer Cells.Oncology research · 2026Article
- Vulvar Rhabdomyosarcoma in an Adult Female Patient: A Case Report and Review of Literature.Acta medica Philippina · 2025Article
- An overview of the presentation and management of vulvovaginal cancers at the NSIA-LUTH Cancer Centre.Ecancermedicalscience · 2025Article
- Article
- Article
- General practitioners' perspectives on statutory skin cancer screening-A questionnaire-based cross-sectional survey in Germany.PloS one · 2024Article
- Common and uncommon lesions of the vulva and vagina on magnetic resonance imaging: correlations with pathological findings.BJR open · 2023Review
- Near complete remission of a locally advanced giant melanoma of the vulva following hypo-fractionated radiotherapy and immune checkpoint inhibitors: A case report.Oncology letters · 2022Article
- Vulvar malignant melanoma: A case report and review of its management.Dermatology reports · 2022Article
- Tubulovillous adenoma with high-grade dysplasia of the vulva harboring high tumor mutational burden and cancer-associated mutations: a case report.Diagnostic pathology · 2022Article
- Perforator flaps for vulvar reconstruction: basic principles.Acta bio-medica : Atenei Parmensis · 2022Article
- Vulvar Malignant Melanoma: A Narrative Review.Cancers · 2022Review
- Genitourinary melanoma: An overview for the clinician.Asian journal of urology · 2022Review
- Management of Early-Stage Vulvar Cancer.Cancers · 2022Review
- Early Diagnostics of Vulvar Intraepithelial Neoplasia.Cancers · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vulvar cancer represents the fourth most common gynecologic malignancy and is often encountered by the general Dermatologist or Gynecologist. Dermatooncologists and Gynecologic Oncologists share expertise in this field and the diagnosis and treatment should ideally be interdisciplinary. All subtypes are typically seen in the later decades of life, although all histologic subtypes have been described in women younger than 30 years. The diagnosis is often delayed. Exact mapping of biopsies is of high importance, as the location and distance from the midline guides the surgical approach depending on the underlying histology. Squamous cell carcinoma accounts for more than 76 % of vulvar cancer with vulvar intraepithelial neoplasia being an important precursor. Basal cell carcinoma is the second most common vulvar malignancy. Melanoma accounts for 5.7 % of vulvar cancer and has a worse prognosis compared to cutaneous melanoma. Most of the trials on checkpoint inhibitors and targeted therapy have not excluded patients with vulvar melanoma and the preliminary evidence is reviewed in the manuscript. Surgery remains the primary treatment modality of locally resectable vulvar cancer. In view of the rarity, the procedure should be performed in dedicated cancer centers to achieve optimal disease control and maintain continence and sexual function whenever possible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.